JP2023510429A5 - - Google Patents

Info

Publication number
JP2023510429A5
JP2023510429A5 JP2022566507A JP2022566507A JP2023510429A5 JP 2023510429 A5 JP2023510429 A5 JP 2023510429A5 JP 2022566507 A JP2022566507 A JP 2022566507A JP 2022566507 A JP2022566507 A JP 2022566507A JP 2023510429 A5 JP2023510429 A5 JP 2023510429A5
Authority
JP
Japan
Prior art keywords
sequence
seq
antigen
hcvr
lcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022566507A
Other languages
English (en)
Japanese (ja)
Other versions
JP7719799B2 (ja
JP2023510429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/070473 external-priority patent/WO2021139682A1/en
Publication of JP2023510429A publication Critical patent/JP2023510429A/ja
Publication of JP2023510429A5 publication Critical patent/JP2023510429A5/ja
Application granted granted Critical
Publication of JP7719799B2 publication Critical patent/JP7719799B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022566507A 2020-01-07 2021-01-06 抗ガレクチン-9抗体およびその使用 Active JP7719799B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062957910P 2020-01-07 2020-01-07
US62/957,910 2020-01-07
PCT/CN2021/070473 WO2021139682A1 (en) 2020-01-07 2021-01-06 Anti-galectin-9 antibody and uses thereof

Publications (3)

Publication Number Publication Date
JP2023510429A JP2023510429A (ja) 2023-03-13
JP2023510429A5 true JP2023510429A5 (https=) 2024-01-16
JP7719799B2 JP7719799B2 (ja) 2025-08-06

Family

ID=74194447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566507A Active JP7719799B2 (ja) 2020-01-07 2021-01-06 抗ガレクチン-9抗体およびその使用

Country Status (11)

Country Link
US (1) US20230054718A1 (https=)
EP (1) EP4087873A1 (https=)
JP (1) JP7719799B2 (https=)
KR (1) KR20220123105A (https=)
CN (2) CN120647763A (https=)
AU (1) AU2021205143A1 (https=)
BR (1) BR112022013494A2 (https=)
CA (1) CA3163988A1 (https=)
IL (1) IL294466A (https=)
MX (1) MX2022008421A (https=)
WO (1) WO2021139682A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
US20260028407A1 (en) 2022-07-15 2026-01-29 Fibrogen, Inc. Modified anti-galectin-9 antibody and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN120585880B (zh) * 2025-08-07 2025-12-09 四川大学华西医院 一种用于预防和/或治疗前列腺癌的联合用药物,其用途及药物组合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CA2348292A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparation
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
DK1638941T3 (da) 2003-05-22 2010-10-11 Abbott Lab Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
CA2541651C (en) 2003-10-22 2011-05-24 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
WO2006076288A2 (en) 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
US7981415B2 (en) 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトcsf−1rに対する抗体及びその使用
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
CA2820642A1 (en) * 2010-12-09 2012-06-14 Galpharma Co., Ltd. Galectin-9-secreting cell, and production method and use of the same
NO2694640T3 (https=) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン,エルエルシー B7−h1およびpd−1に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
FR3021970B1 (fr) 2014-06-06 2018-01-26 Universite Sciences Technologies Lille Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2023510429A5 (https=)
RU2492185C2 (ru) Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование
JP5463036B2 (ja) 可溶性ceaに対する抵抗性を有する医薬抗体組成物
JP2013227339A5 (https=)
JP2013502913A5 (https=)
JP2019532619A5 (https=)
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2021510736A5 (https=)
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
JP2022533538A5 (https=)
EP3189078B1 (en) Anti-ck8 antibodies for use in the treatment of cancers
JP2021528047A5 (https=)
JP2014524902A5 (https=)
CN107660151A (zh) 抗‑cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途
JP2021534735A5 (https=)
EP3092252A1 (en) ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
JP2024532886A5 (https=)
JP2023517754A5 (https=)
JP2021530428A (ja) 頭頸部癌の処置
JP2025510642A5 (https=)
JP2025148452A5 (https=)
JP2020531003A5 (https=)
JP2023517794A5 (https=)
AU2018285523A1 (en) Antibody drug conjugates that bind LGR5